Arrowhead's Flozasiran Demonstrates Up to 81% Reduction in Triglycerides and Prevents Pancreatitis in Phase 3 Trial
Exceptional Lipid-Lowering Efficacy Proven in Phase 3 Trials
Arrowhead Pharmaceuticals' plozasiran, an RNA interference (RNAi) therapeutic targeting Apolipoprotein C-III (APOC3), has demonstrated remarkable results in the SHASTA-3 and SHASTA-4 Phase 3 trials for severe hypertriglyceridemia (sHTG). At 12 months, plozasiran reduced triglyceride levels by 79% and 81%, respectively, showing a significant improvement compared to the placebo group, which experienced a 27% reduction. This confirms the mechanism of action: plozasiran effectively inhibits the production of APOC3, a protein that interferes with triglyceride breakdown in the body, thereby activating lipid metabolism. These findings establish plozasiran as a crucial alternative for patients with severe cases that are difficult to manage with existing treatments.
Significant Reduction in Acute Pancreatitis Incidence and Safety
A key highlight of this trial is the substantial reduction in the risk of acute pancreatitis, the most serious complication of hypertriglyceridemia. Integrated analysis revealed a 78% reduction in acute pancreatitis incidence in the overall treatment group compared to the placebo group. Furthermore, in a high-risk patient group with an extremely high risk of pancreatitis recurrence, the incidence was completely eliminated, demonstrating a 100% reduction. The drug also showed excellent tolerability with no serious adverse events such as thrombocytopenia or liver toxicity, indicating its suitability for long-term administration. This demonstrates not only an improvement in biomarkers but also clinical significance in preventing life-threatening conditions.
Enhanced Convenience Compared to Leading Competitors
The most significant commercial advantage of plozasiran is its significantly longer dosing interval compared to Tryngolza (olezarsen) from Ionis Pharmaceuticals. While Tryngolza requires monthly administration, plozasiran is designed as a subcutaneous injection administered once every three months, dramatically improving patient compliance. This convenience, reducing the dosing frequency by one-third for patients with chronic lipid metabolism disorders, is expected to be a key factor in securing market share. Additionally, the approximately 80% reduction in triglyceride levels observed in the trial provides a clear clinical advantage compared to Tryngolza's 50-70% reduction.
Regulatory Roadmap and Future Market Prospects
Arrowhead has already received its first FDA approval in November 2025 for plozasiran as a treatment for familial chylomicronemia syndrome (FCS), a rare genetic disease. Based on the results of this trial, the company plans to submit a supplemental New Drug Application (sNDA) for sHTG by the end of 2026. The global market for sHTG treatments is currently valued at approximately $1 billion to $2 billion and is rapidly growing due to the increasing prevalence of obesity and metabolic diseases. If plozasiran successfully expands its indications, it will lay the foundation for becoming a blockbuster drug with annual sales of billions of dollars, extending beyond the rare disease market.
Arrowhead's plozasiran has demonstrated overwhelming clinical efficacy compared to existing treatments by reducing triglyceride levels by up to 81% and eliminating acute pancreatitis incidence by up to 100% in the Phase 3 (SHASTA-3/4) trial. This provides a significant short-term impact on market share competition, as it offers a superior once-per-quarter dosing schedule compared to Tryngolza (from Ionis Pharmaceuticals), which received FDA approval in June 2026 and requires monthly administration. The sHTG market in the United States alone is estimated to have approximately 3 million patients, and is projected to grow to $3.6 billion to $4.6 billion by 2030. The expansion of plozasiran's indications will be a key catalyst for increasing corporate value. With the company planning to submit an sNDA to the FDA by the end of 2026, it is expected to establish itself as a blockbuster drug in the lipid metabolism disorder market, which has significant unmet medical needs, in the medium to long term.
Source: BioPharma Dive (rss)